Physician profile
Vikram Shivkumar
NPI 1205129475
$30,922.94
in general payments reported to CMS, 2019-2025
53 companies · $5,608 in 2025
The $5,608 reported for 2025 was more than what 86% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,358 · 2020: $4,482 · 2021: $8,411 · 2022: $1,054 · 2023: $2,417 · 2024: $5,593 · 2025: $5,608.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,204 · Travel and Lodging: $2,174 · Honoraria: $2,000 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,025 · Education: $214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,204.36 |
| Travel and Lodging | $2,173.70 |
| Honoraria | $2,000.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,025.00 |
| Education | $214.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $6,708.22 | 2019-2025 | Austedo Xr, Austedo Xr |
| Sunovion Pharmaceuticals INC. | $5,595.75 | 2020-2022 | |
| Boston Scientific Corporation | $3,536.25 | 2019-2025 | Vercise, General - Dbs |
| Abbott Laboratories | $2,664.30 | 2019-2024 | Infinity |
| Mdd US Operations, LLC | $2,098.63 | 2023-2025 | Gocovri, Gocovri |
| Abbvie INC. | $1,449.94 | 2022-2025 | Duopa, Qulipta, Ubrelvy |
| Medtronic USA, INC. | $1,315.82 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $996.97 | 2019-2025 | Nuplazid, Daybue |
| Ucb, INC. | $861.64 | 2022-2025 | Briviact, Fintepla, Nayzilam |
| Neurocrine Biosciences, INC. | $746.31 | 2022-2025 | Ingrezza, Ongentys |
| Insightec,INC | $525.41 | 2022-2025 | Exablate |
| Allergan, INC. | $447.29 | 2019-2022 | |
| Amgen INC. | $348.48 | 2019-2025 | Uplizna |
| Neurelis, INC. | $307.64 | 2020-2025 | Valtoco |
| Amneal Pharmaceuticals LLC | $297.14 | 2022-2024 | Rytary, Ongentys, Crexont |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $254.55 | 2019-2025 | Spinraza, Skyclarys |
| Sk Life Science, INC. | $218.43 | 2020-2025 | |
| Merz Pharmaceuticals, LLC | $213.86 | 2023-2025 | Xeomin, Inbrija |
| Jazz Pharmaceuticals INC. | $203.73 | 2022-2025 | |
| Lilly USA, LLC | $196.24 | 2020-2024 | Emgality, Reyvow |
| Pfizer INC. | $180.30 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $171.68 | 2023-2025 | Hyqvia, Gammagard |
| Supernus Pharmaceuticals, INC. | $141.37 | 2025 | Qelbree |
| Grifols USA, LLC | $121.27 | 2022-2023 | Gamunex-C |
| Genentech USA, INC. | $115.50 | 2023-2025 | Evrysdi, Ocrevus Zunovo |
| Acorda Therapeutics, INC | $112.81 | 2021-2024 | Inbrija, Ampyra |
| Catalyst Pharmaceuticals, INC. | $101.82 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $101.74 | 2023-2024 | Aptiom |
| Alexion Pharmaceuticals, INC. | $78.17 | 2023-2025 | Ultomiris |
| Otsuka America Pharmaceutical, INC. | $76.38 | 2023-2025 | Nuedexta, Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $75.03 | 2022 | |
| Tanabe Pharma America, INC. | $70.40 | 2022-2024 | |
| Axsome Therapeutics, INC. | $56.60 | 2024-2025 | Symbravo, Sunosi |
| Kyowa Kirin, INC. | $51.48 | 2020-2022 | |
| Csl Behring | $47.96 | 2025 | Hizentra |
| Livanova USA, INC. | $45.37 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Genzyme Corporation | $38.78 | 2019-2025 | |
| Medtronic, INC. | $34.88 | 2021-2023 | Percept PC Brainsense |
| Horizon Therapeutics Plc | $31.48 | 2023 | Uplizna |
| Lundbeck LLC | $27.55 | 2025 | Vyepti |
| Adamas Pharmaceuticals, INC. | $25.84 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $24.65 | 2025 | Wainua |
| Emd Serono, INC. | $24.05 | 2025 | |
| Aucta Pharmaceuticals, INC. | $20.74 | 2025 | Motpoly Xr |
| Cala Health, INC. | $20.46 | 2023 | Cala Trio, Cala Kiq |
| Amylyx Pharmaceuticals, INC. | $19.34 | 2024 | Relyvrio |
| Novartis Pharmaceuticals Corporation | $19.30 | 2019 | |
| Orphalan INC | $18.68 | 2024 | Cuvrior |
| Itf Therapeutics LLC | $18.63 | 2024 | |
| Janssen Pharmaceuticals, INC | $17.90 | 2025 | |
| Janssen Biotech, INC. | $16.86 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $15.36 | 2021 | |
| Cycle Pharmaceuticals INC | $13.96 | 2025 | Tascenso Odt, Bafiertam |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikram Shivkumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.